On 26 September 2025, the first founding meeting of the Nordic Molecular Tumour Board took place, bringing together representatives from molecular tumour board and clinical trial units in Denmark, Norway, Sweden, Finland, and Iceland.
The initiative aims to enhance collaboration across Nordic borders by sharing information on new and upcoming clinical trials, offering patients—particularly those with rare cancers or genetic variants—access to targeted treatments. A molecular tumour board reviews patients who have undergone comprehensive genomic analysis to identify suitable therapies, often through research or industry-led trials.
Set to meet monthly, the Nordic Molecular Tumour Board will discuss cross-border trial opportunities, assist with complex patient cases, and exchange the latest knowledge. This new platform builds on national efforts, elevating the mission to ensure more patients benefit from precision medicine